Niosomes as Novel Drug Carriers: Composition, Preparation, and Applications
DOI:
https://doi.org/10.32628/IJSRST25121198Keywords:
Niosomes, vesicular drug delivery, non-ionic surfactants, cholesterol, controlled release, targeted drug delivery, transdermal deliveryAbstract
Niosomes, vesicular systems derived from non-ionic surfactants, have been identified as highly promising carriers for drug delivery owing to their biocompatibility, stability, and capacity to encapsulate both hydrophilic and lipophilic pharmacological agents. These self-assembled bilayer vesicles, which consist of non-ionic surfactants and cholesterol, present several advantages such as extended circulation duration, targeted therapeutic delivery, and controlled release mechanisms. In comparison to liposomes, niosomes demonstrate superior stability and a diminished vulnerability to oxidative degradation and hydrolytic processes. A variety of formulation techniques, including thin-film hydration, sonication, and reverse-phase evaporation, facilitate the optimization of niosomal formulations for a range of therapeutic applications. Niosomes have been rigorously investigated for their potential applications in transdermal delivery, ocular therapy, pulmonary treatment, oncological therapy, as well as in vaccine and gene delivery systems. Notwithstanding their numerous advantages, obstacles such as vesicle aggregation, drug leakage, and constraints in large-scale manufacturing necessitate further investigation to enhance formulations' stability and commercial feasibility. This review aims to furnish a thorough overview of the composition, preparation methodologies, characterization techniques, and pharmaceutical applications of niosomes, underscoring their promise as an efficacious system for drug delivery within contemporary therapeutics.
Downloads
References
Baillie AJ., Florence AT., Hume LR., Muirhead GT., Rogerson A.,The preparation andproperties of niosomes non-ionic surfactant vesicles. J. Pharm. Pharmacol. 1985, 37: 863-868.
Hunter CA, Dolan TF, Coombs G, Baillie AJ. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol 1988; 40:161-5.
Chandu VP, Arunachalam A, Jeganath S, Yamini K, Tharangini K, Chaitanya G, et al. Niosome: A Novel Drug Delivery System. International Journal of Novel Trends in Pharmaceutical Sciences. 2012;2(1):27-30.
Ahuja N, Saini V, Bishnoi VK, Garg A, Hisoria M, Sharma J, et al. Formulation and evaluation of lansoprazole niosome. Rasayan J Chem. 2008;1(3):561-3.
Salih OS, Samein LH, Ali WK. Formulation and in-vitro evolution of rosuvastatin calcium niosome. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(4):525-35.
Rajera R, Nagpal K, Singh SK, Mishra DN. Niosome: A Controlled and Novel Drug Delivery System. Biological and Pharmaceutical Bulletin. 2011;34(7):945-51.
.Madhavi M, Formulation Meher CP, and Evaluation Pochaiah B, Rao AM. Metformin Based Niosome. International Journal of Pharma Research and Review. 2013;2(1):1.
Pandya KD, Patel SS, Seth AK, Shah CN, Aundhia CJ, Shah NV, et al. NIOSOME: AN Unique Drug Delivery System. Pharma Science Monitor. 2018;7(3):85-92.
Okore VC, Attama AA, Ofokansi KC, Esimone CO, Onuigbo EB. Formulation and Evaluation of Niosomes. Indian Journal of Pharmaceutical Sciences. 2011;73(3):323-5.
N.B.Mahale, P.D.Thakkar,R.G.Mali,D.R.Walunj, and S. R. Chaudhari, “Niosomes: novel sustained release nonionic stable vesicular systems—an overview,” Advances in Colloid and Interface Science,vol.183,pp.46–54,2012.
Z. S.Bayindir,A.Bes ¸ikci, and N. Y¨uksel, “Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics and tissue distribution in rats,” Turkish Journal of Medical Sciences,vol.45,no.6,pp.1403–1412,2015.
S. K. Mehta and N. Jindal, “Tyloxapol niosomes as prospective drug delivery module for antiretroviral drug nevirapine,” AAPS PharmSciTech,vol.16,no.1,pp.67–75,2014.
Sharma D, Ali AAE, Aate JR; Niosomes as Novel Drug Delivery System: Review Article; PharmaTutor; 2018; 6(3); 58-65.
Gayatri Devi S, Venkatesh P, Udupa N. Niosomal sumatriptan succinate for nasal administration. Int J Pharm Sci 2000;62:479-81.
Sharma D, Ali AAE, Aate JR; Niosomes as Novel Drug Delivery System: Review Article; PharmaTutor; 2018; 6(3); 58-65; http://dx.doi.org/10.29161/PT.v6.i3.2018.58
Khandare JN., Madhavi G., Tamhankar BM., Niosomes Novel Drug Delivery System. The Eastern Pharmacist. 1994, 37: 61-64.
Rogerson A., Cummings J., Willmott N., Florence AT., The distribution of doxorubicin in mice following administration in niosomes. J. Pharm. Pharmacol. 1988, 40: 337-342.
Biju SS., Talegaonkar S., Misra PR., Khar RK., Vesicular systems: An overview. Indian J. Pharm. Sci. 2006, 68: 141-153.
Ijeoma F., Uchegbu., Suresh P., Vyas., Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int. J. Pharm. 1998; 172: 33–70.
Udupa N. Niosomes as drug carriers. In: NK Jain. Controlled and novel drug delivery, New Delhi: CBS Publishers and Distributors; 2009. p. 292-303.
Almira I, Blazek Welsh IA, Rhodes GD. Maltodextrin-based proniosomes. AAPS PharmSciTech 2001;3:1-8.
.Alemayehu T, Nisha MJ, Palani S, Anish Z, Zelalem A. Niosomes in targeted drug delivery: some recent advances. Int J Pharm Sci Res 2010;1:1-8.
Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998;172:33-70.
W. Michael, W. Gerhard, H. Heineich, and D. Klaus, “Li posome preparation by single-pass process,” Google Patents, 2010.
Bhaskaran and P. Lakshmi, “Comparative evaluation of niosome formulations prepared by different tech niques,” Acta Pharmaceutica Sciencia, vol. 51, no. 27, p. 32, 2009.
A. J. Baillie, A. T. Florence, L. R. Hume, G. T. Muirhead, and A. Rogerson, “(e preparation and properties of nioso mes—non-ionic surfactant vesicles,” Journal of Pharmacy and Pharmacology, vol. 37, no. 12, pp. 863–868, 1985.
NVSandA.Saini, “Niosomes: a novel drug delivery system,” International Journal Research in Pharmaceutical Chemistry, vol. 1, pp. 498–511, 2011.
A. I. Blazek–Welsh and D. G. Rhodes, “SEM imaging pre dicts quality of niosomes from maltodextrin-based pronio somes,” Pharmaceutical Research, vol.18, no. 5, pp. 656–661, 2001.
A.Manosroi,R.Chutoprapat,M.Abe,andJ.Manosroi,“Char acteristics of niosomespreparedbysupercriticalcarbondioxide (scCO2) fluid,” International Journal of Pharmaceutics,vol.352, no. 1-2, pp. 248–255, 2008.
E. Moazeni,K.Gilani, F. Sotoudegan et al., “Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery,” Journal of Microencapsulation, vol. 27, no. 7, pp. 618–627, 2010.
G.Shilakari Asthana, P. K. Sharma, and A. Asthana, “In vitro and in vivo evaluation of niosomal formulation for con trolled delivery of clarithromycin,” Scientifica, vol. 2016, Article ID 6492953, 10 pages, 2016.
A. R. Mullaicharam and R. S. R. Murthy, “Lung accumulation of niosome-entrapped rifampicin following intravenous and intratracheal administration in the rat,” Journal of Drug Delivery Science and Technology, vol. 14, no. 2, pp. 99–104, 2004
A. Pardakhty, E. Moazeni, J. Varshosaz, V. Hajhashemi, and A. Rouholamini Najafabadi, “Pharmacokinetic study of niosome-loaded insulin in diabetic rats,” DARU Journal of Pharmaceutical Sciences, vol. 19, no. 6, pp. 404–411, 2011.
G. Khaksa, R. D’Souza, S. Lewis, and N. Udupa, “Pharma cokinetic study of niosome encapsulated insulin,” Indian Journal of Experimental Biology, vol. 38, no. 9, pp. 901–905, 2000.
M.Shatalebi, S. Mostafavi, and A. Moghaddas, “Niosome as a drug Carrier for topical delivery of N-acetyl glucos amine,” Research in Pharmaceutical Sciences, vol. 5, no. 2, p. 107, 2010.
S. Moghassemi, A. Hadjizadeh, and K. Omidfar, “Formu lation and characterization of bovine serum albumin-loaded niosome,” AAPSPharmscitech, vol.18, no.1, pp. 27–33, 2017.
L. Kanaani, I. Javadi, M. Ebrahimifar, H. E. Shahmabadi, A. A. Khiyaviand, and T. Mehrdiba, “Effects of cisplatin loaded niosomal nanoparticleson BT-20 human breast carcinoma cells,” Asian Pacific Journal of Cancer Prevention: APJCP, vol. 18, no. 2, pp. 365–368, 2017.
A. Abdelbary, H. F. Salem, and R. A. Khallaf, “Niosomal 5 Flourouracil gel for effective treatment of skin cancer; In vitro and In-vivo evaluation,” International Journal of Drug Delivery, vol. 7, no. 4, pp. 223–232, 2016.
D. Paolino, D. Cosco, R. Muzzalupo, E. Trapasso, N. Picci, and M Fresta, “Innovative bola-surfactant niosomes as topical delivery systems of 5-fluorouracil for the treatment of skin cancer,” International Journal of Pharmaceutics, vol. 353, no. 1-2, pp. 233–242, 2008.
I. A. Alvi, J. Madan, D.Kaushik, S. Sardana, R.S. Pandey, and A. Ali, “Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cellsreparation, characterization, in-vitro release, and cyto toxicity analysis,” Anti-Cancer Drugs, vol. 22, no. 8, pp. 774–782, 2011.
U. S. Suma, S. Parthiban, G. P. Senthil Kumar, and T. Tamiz Mani, “Effect of span-80 in the formulation lamivudine niosomal gel,” Asian Journal of Research in Biological and Pharmaceutical Sciences, vol. 4, no. 1, pp. 35–45, 2015.
H. M. Shreedevi, J. A. J. Nesalin, and T. Tamizh Mani, “Development and evaluation of stavudine niosome by ether injection method,” International Journal of Pharma Sciences and Research, vol. 7, no. 1, pp. 38–46, 2016.
K. Ruckmani and V. Sankar, “Formulation and optimization of zidovudine niosomes,” AAPS PharmSciTech, vol.11, no. 3, pp. 1119–1127, 2010.
P. Ranga, R. Natarajan, and N. Rajendran, “Formulation and evaluation of zidovudine loaded niosomes,” Journal of Pharmaceutical Nanotechnology, vol. 1, pp. 12–18, 2013.
P. N. Gupta, V. Mishra, A. Rawat et al., “Non-invasive vaccine delivery in transfersomes, niosomes and lipo somes: a comparative study,” International Journal of Pharmaceutics, vol. 293, no. 1-2, pp. 73–82, 2005.
V. C. Okore, A. A. Attama, K. C. Ofokansi, C. O. Esimone, and E. B. Onuigbo, “Formulation and evaluation of nio somes,” Indian Journal of Pharmaceutical Sciences, vol. 73, no. 3, pp. 323–328, 2011.
C. O.Rentel, J. A. Bouwstra, B. Naisbett, and H. E. Junginger, “Niosomes as a novel peroral vaccine delivery system,” In ternational Journal of Pharmaceutics, vol. 186, no. 2, pp. 161–167, 1999.
S. Jain and S. P. Vyas, “Mannosylated niosomes as Carrier adjuvant system for topical immunization,” Journal of Pharmacy and Pharmacology, vol. 57, no. 9, pp. 1177 1184, 2005.
Ammar HO, Haider M. In vitro and in vivo investigation for optimization of niosomal ability for sustainment and bioavailabilty enhancement of diltiazem after nasal administration. Drug Delivery 2017;24:414-21.
Moghddam SR, Ahad A, Aqil M, Imam SS, Sultana Y. Formulation and optimization of niosomes topical diacerin delivery using 3 factor, 3-level. Box-Behnken design for the management of psoriasis. Mater Sci Eng C Mater Biol Appl 2016;69:789-97.
Yuksel N, Bayindir ZS, Aksakal E, Ozcelikay AT. Insitu Niosome forming maltodextrin proniosome of candesartan cilexetil: In vitro and in vivo evaluation of in-situ niosome forming proniosomes containing candesartan cilexetil. Int J Biol Macromol 2015;82:453-63.
Vyshnavi V, Indira S, Prathima Srinivas. Formulation and evaluation of nasal niosomal in-situ gels of loratidine. Int J Pharm Sci Drug Res 2015;7:13-2.
Kaushik Kar, Preethi Sudheerl. Formulation and evaluation of niosomal drug delivery system of ketoprofen. J Pharm Sci 2015;5:173-80.
Ajay Aggarwal, Kamal Saroha, Sanju Nanda. Formulation, evaluation, and comparison of ketorolac tromethamine transdermal gel containing natural and synthetic permeation enhancers. Der Pharmacia Sinica 2014;5:41-5.
Sunil Kamboj, Vipin Saini, Suman Bala. Formulation and characterization of drug loaded non-ionic surfactant vesicles (Niosomes) for oral bioavailabilty enhancement. Sci Wor J 2014:8. http://dx.doi.org/10.1155/2014/959741.
Nagaraju Ravouru, Pallavi Kondreddy, Deepathy Korakanchi, Haritha M. Formulation and evaluation of niosomal nasal drug delivery system of folic acid for brain targeting. Curr Drug Discovery Technol 2013;10:210-82.
Okore VC, Attarna AA, Ofokansi KC, Esimone CO. Formulation and evaluation of Niosomes. Ind J Pharm Sci 2011;73:323-8.
Kandasamy Ruckmani, Veintramuthu Sankar. Formulation and optimization of zidovudine niosomes. AAPS PharmaSciTech 2010;11:1119-27.
Pratap S Jadon, Virendra Gajbhiye, Rajesh S Jadon. Enhanced oral bioavailabilty of griseofulvin via niosomes. AAPS PharmSciTech 2009;10:4.
Rajalakshmi SV, Vinaya OG. Formulation development, evaluation and optimization of medicated lip rouge containing niosomal acyclovir for the management of recurrent herpes labialis. Int J Appl Pharm 2017;9:21-7.
M. Bragagni, N. Mennini, C. Ghelardini, and P. Mura, “Devel opment and characterization of niosomal formulations of doxorubicin aimed at brain targeting,” Journal of Pharmacy and Pharmaceutical Sciences,vol.15,no.1,pp.184–196,2012.
M. Bragagni, N. Mennini, S. Furlanetto, S. Orlandini, C. Ghelardini, and P. Mura, “Development and characterization of functionalized niosomes for brain targeting of dynorphin-B,” European Journal of Pharmaceutics and Biopharmaceutics,vol. 87,no.1,pp.73–79,2014.
C. Dufes, F. Gaillard, I. F. Uchegbu, A. G. Sch¨atzlein, J.-C. Olivier, and J.-M. Muller, “Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain,” International Journal of Pharmaceutics,vol.285,no.1-2,pp.77–85,2004.
L.Tavano, R.Muzzalupo,L.Mauro,M.Pellegrino,S.And` o,and N. Picci, “Transferrin-conjugated Pluronic niosomes as a new drug delivery system for anticancer therapy,” Langmuir,vol.29, no.41,pp.12638–12646,2013.
L.Tavano,M.Vivacqua,V.Carito,R.Muzzalupo,M.C.Caroleo, and F. Nicoletta, “Doxorubicin loaded magneto-niosomes for targeted drug delivery,” Colloids and Surfaces B: Biointerfaces, vol. 102, pp. 803–807, 2013.
M.Hong,S.Zhu,Y.Jiang,G.Tang,andY.Pei,“Efficienttumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin,” Journal of Controlled Release, vol. 133,no.2,pp.96–102,2009.
C. Dufes, J.-M. Muller, W. Couet, J.-C. Olivier, I. F. Uchegbu, andA.G.Sch¨atzlein, “Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles,” Pharmaceutical Research, vol.21,no.1,pp.101–107,2004.
S. Pawar and P. Vavia, “Glucosamine anchored cancer targeted nano-vesicular drug delivery system of doxorubicin,” Journal of Drug Targeting,vol.24,no.1,pp.68–79,2016.
Lorena, T.; Rita, M.; Loredana, M.; Michele, P.; Sebastiano, A.; Nevio, P. Transferrin-conjugated pluronic niosomes as a new drug delivery system for anticancer therapy. Langmuir Acs J. Surf. Colloids 2013, 29, 12638–12646.
Junyaprasert, V.B.; Singhsa, P.; Jintapattanakit, A. Influence of chemical penetration enhancers on skin permeability of ellagic acid-loaded niosomes. Asian J. Pharm. Sci. 2013, 8, 110–117.
Sarthak, M.; Chiranjib, B.; Surajit, G.; Jagannath, K.; Nilmoni, S. Modulation of the photophysical properties of curcumin in nonionic surfactant (Tween-20) forming micelles and niosomes: A comparative study of different microenvironments. J. Phys. Chem. B 2013, 117, 6957.
Jiradej, M.; Narinthorn, K.; Worapaka, M.; Friedrich, G.T.; Werner, R.G.; Aranya, M. Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: Potential application in vitiligo treatment. J. Pharm. Sci. 2010, 99, 3533–3541.
Attia, N.; Mashal, M.; Grijalvo, S.; Eritja, R.; Zárate, J.; Puras, G.; Pedraz, J.L. Stem cell-based gene delivery mediated by cationic niosomes for bone regeneration. Nanomed. Nanotechnol. Biol. Med. 2017, 14, 521–531.
Puras, G.; Mashal, M.; Zárate, J.; Agirre, M.; Ojeda, E.; Grijalvo, S.; Eritja, R.; Diaz-Tahoces, A.; Navarrete, G.M.; Avilés-Trigueros, M. A novel cationic niosome formulation for gene delivery to the retina. J. Control. Release 2014, 174, 27–36.
Pardakhty, A.; Varshosaz, J.; Rouholamini, A. In vitro study of polyoxyethylene alkyl ether niosomes for delivery of insulin. Int. J. Pharm. 2007, 328, 130–141.
Dufes, C.; Gaillard, F.; Uchegbu, I.F.; Schätzlein, A.G.; Olivier, J.C.; Muller, J.M. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int. J. Pharm. 2004, 285, 77–85.
Wilkhu, J. Non-Ionic Surfactant Technology for the Delivery and Administration of Sub-Unit Flu Antigens. Ph.D. Thesis, Aston University, Birmingham, UK, 2013.
Malhotra M., Jain N.K., Niosomes as Drug Carriers. Indian Drugs. 1994, 31(3): 81-866.
Weissman G, Bloomgarden D, Kaplan R, Cohen C, Hoffstein S, Collins T, et al. A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells. Proc Natl Acad Sci 1975;72:88-92.
Sternberg B, Uchegbu IF, Florence AT and Murdan S. 1998.
Theresa MA. Drugs published by ADIS international Ltd. 1998; 56(5):747-756.
Buckton G and Harwood. Interfacial Phenomena in Drug Delivery and Targeting Academic Publishers, Switzerland. 1995;154-155.
D. Pozzi, R. Caminiti, C. Marianecci et al., “Effect of cholesterol on the formation and hydration behavior of solid-supported niosomal membranes,” Langmuir,vol.26,no.4,pp.2268–2273, 2010.
D. Akhilesh, K. B. Bini, and J. V. Kamath, “Review on span-60 based non-ionic surfactant vesicles (niosomes) as novel drug delivery,” International Journal of Research in Pharmaceutical and Biomedical Sciences,vol.3,pp.6–12,2012.
Pawar SD, Pawar RG, Kodag PP, Waghmare AS. Niosome: An Unique Drug Delivery System. International Journal of Biology, Pharmacy and Allied Sciences. 2012;3(1):409-12.
Selvaraj S, Niraimathiand V, Nappinnai M. Formulation and evaluation of acyclovir loaded chitosan nanoparticles. International Journal of Pharmacy and Analytical Research. 2017;9(3):118-25.
Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol 1985;37:237-42.
Biswal S, Murthy PN, Sahu J, Sahoo P, Amir F. Vesicles of non ionic surfactants (Niosomes) and drug delivery potential. Int J Pharma Sci Nanotechnol 2008;1:1-8.
Navneet Kumar Verma, Asha Roshan. Niosomes and its application:A Review, IJRPLS, 2014; 2(1): 182-184.
Kong MH, Park C, Feng L, Hou X, Cheng X Chen. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydrate Polymers 2013;94:634-41.
Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS PharmSciTech 2008;9:740-7.
Korkmaz M, Ozer AY, Hincal AA. DTPA niosomes in diagnostic imaging. ed. by Uchegbu IF. Harwood Academic Publishers, Singapore; 2000. p. 227-42.
Raghavachari N, Fahl W. Targeted gene delivery to skin cells in vivo: a comparative study of liposomes and polymers as delivery vehicles. J Pharm Sci 2002;91:615-22.
Raja N, Udupa N, Uma D. Effect of macrophage activation on niosome encapsulated bleomycin in tumor-bearing mice. Ind J Pharmacol 1996;28:175-80.
Moser P, Marchand Arvier M, Labrude P, Vigneron C. Hemoglobin niosomes. II. In vitro interactions of plasma proteins and phagocytes. Pharm Acta Helv 1990;65:82-92.
Vyas SP, Singh RP, Jain S, Mishra V, Mahor S, Singh P, et al. Non ionic surfactant based vesicles (niosomes) for non-invasive topical genetic immunization against hepatitis B. Int J Pharm 2005;296:80-6.
I. F. Uchegbu and S. P. Vyas, “Non-ionic surfactant based vesicles (niosomes) in drug delivery,” International Journal of Pharmaceutics,vol.172,no.1-2,pp.33–70,1998.
S. Verma, S. K. Singh, N. Syan, P. Mathur, and V. Valecha, “Nanoparticle vesicular systems: a versatile tool for drug deliv ery,” Journal of Chemical and Pharmaceutical Research,vol.2, no. 2, pp. 496–509, 2010.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 International Journal of Scientific Research in Science and Technology
This work is licensed under a Creative Commons Attribution 4.0 International License.
